Nutriband Inc
Research Nutriband Inc (NTRB) on Bullrun: market cap USD 71.11M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNTRB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 71.11M
- Financial periodFY2026
- RevenueUSD 2.04M
- Revenue growth-4.8%
- Net income-USD 8.23M
- Free cash flow-USD 5.14M
- Gross margin27.8%
Valuation Snapshot
latest market cap is USD 71.11M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 2.04M | -USD 8.23M | -USD 5.14M | 27.8% | -2.58 | USD 4.57M | USD 245.49K | USD 6.68M |
| FY2025 | USD 2.14M | -USD 10.48M | -USD 4.72M | 34.7% | -0.99 | USD 4.31M | USD 186.35K | USD 6.43M |
| FY2024 | USD 2.09M | -USD 5.49M | -USD 3.58M | 41.3% | -0.69 | USD 492.94K | USD 2.00M | USD 6.44M |
| FY2023 | USD 2.08M | -USD 4.48M | -USD 3.07M | 36.1% | -0.53 | USD 1.99M | USD 185.81K | USD 8.57M |
| FY2022 | USD 1.42M | -USD 6.18M | -USD 2.89M | 39.0% | -0.8 | USD 4.89M | USD 134.57K | USD 11.86M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 71.11M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 55.27M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 52.31M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 19.63M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 28.28M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 78.36M | n/a | n/a | n/a |
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nutriband Inc's market cap?
Nutriband Inc's market capitalization is USD 71.11M.
What does Nutriband Inc do?
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.